Loading company
Climb Bio, Inc.
CLYM · Nasdaq · ·
Next earnings: November 5, 2026
$11.52-2.0%Sep 29 close
- 1M
- -20.9%
- 6M
- +76.1%
- 1Y
- +473.1%
- 5Y
- -33.1%
CLYM · Nasdaq · ·
Next earnings: November 5, 2026
$11.52-2.0%Sep 29 close
Climb Bio, Inc. is scheduled to report next on November 5, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Profit | -$13.5M | -$8.7M | -55.76% |
| Profit per share | -$0.18 | -$0.13 | -38.46% |
| Free Cash Flow | -$15.6M | -$947K | -1,551.00% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Climb Bio, Inc. has no earnings call transcript available.
“2026 is proving to be a defining year for Climb Bio, and I am thrilled by the team’s execution ,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Climb Bio, Inc. is a clinical-stage biotechnology company with a mission to deliver high impact, disease-modifying medicines for individuals living with immune-mediated diseases, including those affecting kidney health. The Company’s pipeline includes, budoprutug, an anti-CD19 monoclonal antibody that has potential to treat a broad range of B-cell mediated diseases, and CLYM116, an anti-APRIL monoclonal antibody being developed for IgA nephropathy.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Climb Bio, Inc.’s Item 2.02 8-K filed August 6, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.